Bacterial Infections Clinical Trial
Official title:
Prevalence of MRSA in Skin and Soft Tissue Infections in Two Ontario Emergency Departments.
Staphylococcus aureus is the most common bacteria responsible for skin, bone, and muscle infections. Recent studies from the United States have suggested that a type of this bacterium called methicillin resistant S. aureus (MRSA) has become dramatically more common, especially the community strain. However, Canadian data is still largely lacking. This study aims to determine the prevalence of community acquired (CA) MRSA among patients presenting with skin and soft tissue infections to the Urgent Care Center and Emergency Departments in London, Ontario. This will be determined by taking swabs at enrollment from patient's noses, throats, and sites of infection. Patients will be asked to complete a health questionnaire with the goal of identifying risk factors associated with CA-MRSA. Through follow-up swabs of participants' noses and throats at one and three months, the effects of treatment on patient's carrying MRSA will be determined. Results may be used to form guidelines for empirical S aureus treatment in the region, reducing possible morbidity and mortality from delayed or suboptimal treatment of CA-MRSA infections. Improved understanding of risk factors associated with MRSA infection in a Canadian setting, may also change the practice of physicians considering empiric antibiotic therapy for skin and soft tissue infections.
Objective & Hypothesis: The objective of this prospective study is to determine the
prevalence of MRSA and community acquired MRSA (CA-MRSA) in adult patients (>17yrs old)
presenting with skin or soft tissue infections to the emergency departments (EDs) of an
academic health care setting in London, Ontario. Secondary objectives will include the
identification of demographic and clinical variables associated with MRSA, characterization
of MRSA antimicrobial susceptibilities and genotypes, and determining the effects of
treatment on MRSA colonization. We believe that the prevalence of MRSA and CA-MRSA in
London, Ontario will be lower than rates recently published by academic hospitals from the
United States. The hypothesis of the study is that patients presenting to the Emergency
Departments in London, Ontario with skin and soft tissue infections will have a 10%
prevalence of CA-MRSA, but certainly the prevalence may be much higher.
Purpose: Results from this research may be used as part of the guidelines for empirical S
aureus treatment in the region, thus reducing possible morbidity and mortality from delayed
or suboptimal treatment of CA-MRSA infections. This information, along with an improved
understanding of risk factors associated with MRSA infection in a Canadian setting, has the
potential to change the practice of physicians who are considering empiric antibiotic
therapy for skin and soft tissue infections.
This study will focus on the epidemiology of patients with skin or soft tissue infections
presenting to the adult emergency departments (EDs) at the London Health Sciences Centre
(LHSC) and the Urgent Care Center at St. Joseph's Health Centre (SJHC). By using a
comparison group of non CA-MRSA infections, the proportion of CA-MRSA with relation to the
total MRSA and methicillin sensitive Staphylococcus aureus (MSSA) in the region will be
investigated. The study will also investigate the risk factors in the CA-MRSA population
including: demographics, housing history, contact with the health care system, past CA-MRSA
infection, asymptomatic CA-MRSA colonization, colonization/infection of close contacts,
involvement in contact sports/team sports, hygienic body shaving, chronic skin disorders,
recurrent/recent antibiotic use, IV drug use, contact with incarcerated individuals, and
chronic disease.
Through follow-up visits at one and three months involving nares and throat swabs of
patients initially testing positive for MRSA the effects of treatment on MRSA colonization
will be determined. Furthermore, a follow-up questionnaire will be administered to all
patients at one month to determine complication rates for patients colonized with MRSA
versus those not colonized.
The current recommendations for antibiotic treatment of unknown S. aureus infection are
based on clinical judgment, and therefore an understanding of regional incidence and
susceptibility of CA-MRSA are essential for empiric treatment. Through the microbiological
analysis of the cases, laboratory parameters and antibiotic susceptibility of CA-MRSA
presenting to LHSC will be established. As well, the clinical characteristics of these
patients will be documented to aid clinicians in recognizing patients presenting with
CA-MRSA.
Experimental Design: This study will be a prospective prevalence study involving adult
patients (>17years old) with skin and soft-tissue infections presenting to the Emergency
Departments of LHSC (University Hospital and Victoria Hospital) as well as to the Urgent
Care of SJHC. These departments have a combined approximate total of 150,000 visits per
year. The study has an expected enrollment of 152 patients from July 2008- July 2009. The
study will continue until three months after the last patient has been enrolled so that
follow-up nasal and throat swabs may be obtained, if applicable.
n = Z2 P (1-P) / d2 n = 1.962 * .10 (1- .10) / 0.052 n = 3.8416 * .10 * .90 / .0025 n = 138
While the investigators do not anticipate a problem with non-response or missing values, to
take this into consideration, we will over-sample the above sample size by 10%. Therefore,
we will recruit at least 152 patients to the study. Therefore, assuming 80% power, an
estimated prevalence of 10%, and a precision level of 5%, 152 patients are needed to be 95%
confident that the true proportion of MRSA in adult patients (>17yrs old) presenting with
skin or soft tissue infections will be between 5% and 15%.
Written, informed consent will be obtained from all patients that meet the study inclusion
criteria.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03726216 -
Xydalba Utilization Registry in France
|
||
Completed |
NCT03605498 -
OR PathTrac (Tracking Intra-operative Bacterial Transmission)
|
||
Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Recruiting |
NCT02074865 -
Children's Antibiotic Resistant Infections in Low Income Countries
|
N/A | |
Completed |
NCT01932034 -
Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
|
N/A | |
Completed |
NCT01689207 -
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
|
Phase 1 | |
Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
Not yet recruiting |
NCT01159470 -
The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children
|
N/A | |
Completed |
NCT00983255 -
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
|
Phase 1 | |
Completed |
NCT00678106 -
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
|
Phase 1 | |
Completed |
NCT00799591 -
French Study In ICU Patients Treated With Tigecycline
|
N/A | |
Completed |
NCT01074775 -
Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection
|
N/A | |
Completed |
NCT00478855 -
Tazocin Intervention Study
|
Phase 4 | |
Terminated |
NCT00431028 -
Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT05684705 -
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
|
Phase 1 | |
Recruiting |
NCT03858387 -
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
|
||
Enrolling by invitation |
NCT04764058 -
Efficacy and Safety of Colistin Based Antibiotic Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 |